Generated: December 18, 2017
DrugPatentWatch Database Preview
Details for Patent: 9,132,239
« Back to Dashboard
Which drugs does patent 9,132,239 protect, and when does it expire?
Patent 9,132,239 protects NORDITROPIN FLEXPRO, LEVEMIR FLEXTOUCH, NOVOLOG FLEXTOUCH, FIASP FLEXTOUCH, RYZODEG 70/30, SAXENDA, TRESIBA, and XULTOPHY 100/3.6, and is included in eight NDAs.
This patent has eleven patent family members in ten countries.
Summary for Patent: 9,132,239
|Title:||Dial-down mechanism for wind-up pen|
|Abstract:|| The present invention relates to a dial-down mechanism for an injection device comprising a torsion spring for assisting injection of a dose of medicament from the injection device, the dial-down mechanism comprising a ratchet arm (21) engaging a ring element (10) and a reset element (30) which acts on a knob located on the periphery of the ratchet arm (21) to move the ratchet arm (21) out of engagement with the ring element (10) in order to allow the set dose to be reduced.|
|Inventor(s):|| Moller; Claus Schmidt (Fredensborg, DK), Markussen; Tom Hede (Bagsv.ae butted.rd, DK), Radmer; Bo (Hillerod, DK), Enggaard; Christian Peter (Vejby, DK) |
|Assignee:|| Novo Nordisk A/S (Bagsvaerd, DK) |
Patent Claim Types:|
see list of patent claims
|Use; Device; |
||Patented / Exclusive Use
|Novo Nordisk Inc||NORDITROPIN FLEXPRO||somatropin recombinant||INJECTABLE;INJECTION||021148-008||Mar 1, 2010||BX||RX||No||No||► Subscribe||► Subscribe||Y||► Subscribe|
|Novo Nordisk Inc||NORDITROPIN FLEXPRO||somatropin recombinant||INJECTABLE;INJECTION||021148-009||Mar 1, 2010||BX||RX||No||No||► Subscribe||► Subscribe||Y||► Subscribe|
|Novo Nordisk Inc||NORDITROPIN FLEXPRO||somatropin recombinant||INJECTABLE;INJECTION||021148-010||Mar 1, 2010||RX||No||No||► Subscribe||► Subscribe||Y||► Subscribe|
|Novo Nordisk Inc||NORDITROPIN FLEXPRO||somatropin recombinant||INJECTABLE;INJECTION||021148-011||Jan 23, 2015||RX||No||No||► Subscribe||► Subscribe||Y||► Subscribe|
|Novo Nordisk Inc||LEVEMIR FLEXTOUCH||insulin detemir recombinant||INJECTABLE;SUBCUTANEOUS||021536-005||Oct 31, 2013||RX||Yes||Yes||► Subscribe||► Subscribe||Y||► Subscribe|
|Novo Nordisk Inc||NOVOLOG FLEXTOUCH||insulin aspart recombinant||INJECTABLE;SUBCUTANEOUS||020986-005||Oct 31, 2013||RX||Yes||Yes||► Subscribe||► Subscribe||Y||► Subscribe|
|Novo Nordisk Inc||FIASP FLEXTOUCH||insulin aspart recombinant||SOLUTION;SUBCUTANEOUS||208751-002||Sep 29, 2017||RX||Yes||Yes||► Subscribe||► Subscribe||Y||► Subscribe|
|Novo Nordisk Inc||RYZODEG 70/30||insulin aspart; insulin degludec||SOLUTION;SUBCUTANEOUS||203313-001||Sep 25, 2015||RX||Yes||Yes||► Subscribe||► Subscribe||Y||► Subscribe|
|Novo Nordisk Inc||SAXENDA||liraglutide recombinant||SOLUTION;SUBCUTANEOUS||206321-001||Dec 23, 2014||RX||Yes||Yes||► Subscribe||► Subscribe||Y||► Subscribe|
|Novo Nordisk Inc||TRESIBA||insulin degludec||SOLUTION;SUBCUTANEOUS||203314-001||Sep 25, 2015||RX||Yes||No||► Subscribe||► Subscribe||Y||► Subscribe|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
Foreign Priority and PCT Information for Patent: 9,132,239
|Foriegn Application Priority Data|
||Foreign Patent Number
||Foreign Patent Date
|08167547||Oct 24, 2008|
|PCT Filed||October 21, 2009||PCT Application Number:||PCT/EP2009/063801|
|PCT Publication Date:||April 29, 2010||PCT Publication Number:||
International Patent Family for Patent: 9,132,239
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.